Francis Vacherot

List of Publications by Year
in descending order

54 papers	2,138 citations	201674 27 h-index	233421 45 g-index
54 all docs	54 docs citations	54 times ranked	3149 citing authors

#	Article	IF	Citations
1	Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate, 2009, 69, 1774-1780.	2.3	227
2	Prostate Cancer Antigen 3 Score Accurately Predicts Tumour Volume and Might Help in Selecting Prostate Cancer Patients for Active Surveillance. European Urology, 2011, 59, 422-429.	1.9	136
3	Class III Î²-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy. Cancer Research, 2010, 70, 9253-9264.	0.9	135
4	Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clinical Cancer Research, 2003, 9, 1801-7.	7.0	120
5	Prostate Cancer Detection Rate in Patients with Repeated Extended 21-Sample Needle Biopsy. European Urology, 2009, 55, 600-609.	1.9	114
6	A Human- and Male-Specific Protocadherin that Acts through the Wnt Signaling Pathway to Induce Neuroendocrine Transdifferentiation of Prostate Cancer Cells. Cancer Research, 2005, 65, 5263-5271.	0.9	111
7	Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. Journal of Cellular Biochemistry, 2006, 99, 402-410.	2.6	91
8	Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract ofSerenoa repens (LSESr, Permixonï¿½) in benign prostatic hyperplasia. Prostate, 2000, 45, 259-266.	2.3	65
9	The NF-ÎºB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?. World Journal of Urology, 2007, 25, 477-489.	2.2	64
10	Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal followâ€up from a prospective trial. BJU International, 2013, 111, 988-996.	2.5	57
11	The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene, 2002, 21, 7861-7871.	5.9	55
12	The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU International, 2012, 110, 43-49.	2.5	53
13	Prospective Evaluation of an Extended 21-Core Biopsy Scheme as Initial Prostate Cancer Diagnostic Strategy. European Urology, 2014, 65, 154-161.	1.9	52
14	Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology, 2005, 66, 930-934.	1.0	49
15	Glycosaminoglycans Differentially Bind HARP and Modulate Its Biological Activity. Journal of Biological Chemistry, 1999, 274, 7741-7747.	3.4	48
16	Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Molecular Cancer, 2010, 9, 89.	19.2	48
17	Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer. Neoplasia, 2013, 15, 761-IN22.	5.3	47
18	Neuroendocrine Differentiation in Prostate Cancer: From Lab to Bedside. Urologia Internationalis, 2007, 79, 287-296.	1.3	44

#	Article	IF	Citations
19	Should We Investigate Prostatic Inflammation for the Management of Benign Prostatic Hyperplasia?. European Urology Supplements, 2009, 8, 879-886.	0.1	40
20	Protocadherin-PC promotes androgen-independent prostate cancer cell growth. Prostate, 2006, 66, 1100-1113.	2.3	35
21	Human hormone-refractory prostate cancers can harbor mutations in the O 2 -dependent degradation domain of hypoxia inducible factor-1Î± (HIF-1Î±). Journal of Cancer Research and Clinical Oncology, 2002, 128, 358-362.	2.5	34
22	Nitrosulindac (NCX 1102): A new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate, 2004, 61, 132-141.	2.3	32
23	Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer. Cancer, 2015, 121, 1422-1430.	4.1	31
24	Involvement of heparin affin regulatory peptide in human prostate cancer. , 1999, 38, 126-136.		29
25	Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa). Journal of Steroid Biochemistry and Molecular Biology, 2008, 109, 158-167.	2.5	29
26	Transforming growth factor Î²â€receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU International, 2011, 108, E23-8.	2.5	29
27	The Risk of Upstaged Disease Increases with Body Mass Index in Low-Risk Prostate Cancer Patients Eligible for Active Surveillance. European Urology, 2012, 61, 356-362.	1.9	28
28	Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling. Cancer Letters, 2017, 410, 100-111.	7.2	28
29	Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU International, 2004, 94, 524-527.	2.5	27
30	Lipidosterolic Extract of Serenoa Repens Modulates the Expression of Inflammation Related-Genes in Benign Prostatic Hyperplasia Epithelial and Stromal Cells. International Journal of Molecular Sciences, 2013, 14, 14301-14320.	4.1	27
31	BPH Gene Expression Profile Associated to Prostate Gland Volume. Diagnostic Molecular Pathology, 2008, 17, 207-213.	2.1	26
32	Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines. Cancer Letters, 2005, 218, 163-170.	7.2	23
33	Androgens regulate Hedgehog signalling and proliferation in androgenâ€dependent prostate cells. International Journal of Cancer, 2012, 131, 1297-1306.	5.1	23
34	Pathological findings and prostateâ€specific antigen outcomes after laparoscopic radical prostatectomy for highâ€risk prostate cancer. BJU International, 2010, 106, 86-90.	2.5	21
35	Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate. Journal of Steroid Biochemistry and Molecular Biology, 2015, 152, 89-100.	2.5	21
36	CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget, 2015, 6, 11994-12008.	1.8	20

#	Article	IF	Citations
37	Biochemical and mitogenic properties of the heparin-binding growth factor HARP. Progress in Growth Factor Research, 1995, 6, 25-34.	1.6	17
38	Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. Oncotarget, 2016, 7, 69397-69411.	1.8	17
39	Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1060-1066.	1.6	16
40	Upregulation of heparin-affin regulatory peptide by androgen. In Vitro Cellular and Developmental Biology - Animal, 1995, 31, 647-648.	1.5	15
41	Gefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor Activation. Clinical Cancer Research, 2006, 12, 2937-2943.	7.0	15
42	Androgenic hormones and the excess male mortality observed in COVID-19 patients: new convergent data. World Journal of Urology, 2021, 39, 3121-3123.	2.2	15
43	Contemporary pathologic characteristics and oncologic outcomes of prostate cancers missed by 6- and 12-core biopsy and diagnosed with a 21-core biopsy protocol. World Journal of Urology, 2013, 31, 869-874.	2.2	7
44	Overexpression of Nucleolin and Associated Genes in Prostate Cancer. International Journal of Molecular Sciences, 2022, 23, 4491.	4.1	7
45	INFLAMMATION IN PROSTATIC TISSUE IS ASSOCIATED WITH SYMPTOMATIC BPH, IPSS AND PROSTATE VOLUME!. Journal of Urology, 2009, 181, 504-504.	0.4	5
46	Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance. Cancers, 2021, 13, 3791.	3.7	5
47	1619: Plasma Estrogens in Newly Diagnosed Patients for Prostate Cancer. Journal of Urology, 2007, 177, 536-536.	0.4	0
48	THE EFFECT OF PROTOCADHERIN-PC (PCDH-PC) EXPRESSION ON THE INVASIVE PHENOTYPE OF PROSTATE CANCER CELLS. Journal of Urology, 2008, 179, 425-425.	0.4	0
49	376 HEDGEHOG/GLI SUPPORTS ANDROGEN SIGNALING IN ANDROGEN DEPRIVED AND ANDROGEN INDEPENDENT PROSTATE CANCER CELLS. Journal of Urology, 2010, 183, .	0.4	0
50	413 INHIBITION OF CASTRATION- AND CHEMO-RESISTANT PROSTATE TUMOR GROWTH BY THE MULTIVALENT PSEUDOPEPTIDE NUCANT 6L. Journal of Urology, 2011, 185, .	0.4	0
51	MP55-09 PRE-CLINICAL EVALUATION OF THE NOVEL THERAPIES OF THE CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.4	0
52	1012: Adjuvant Androgen Deprivation and Chemotherapy for Patients with High Risk Prostate Cancer Progression After Radical Prostatectomy: Preliminary Study on Toxicity and Side Effects. Journal of Urology, 2007, 177, 334-334.	0.4	0
53	Abstract 661: Efficiency of the multivalent pseudopeptide nucant 6L in castration- and chemo-resistant prostate cancers. , 2011, , .		0
54	Fibroblast growth factor signaling as a bypass mechanism of the androgen receptor pathway: new perspectives for castration-resistant prostate cancer. Translational Cancer Research, 2018, 7, S449-S452.	1.0	0